RT Generic
T1 Neoplasias en pacientes receptores de trasplante renal.
T2 Neoplasms in kidney transplant recipients.
A1 Pérez Chapinal, Raúl
AB Introducción: El trasplante renal es el tratamiento que mayor supervivencia y calidad de vida ofrece en la enfermedad renal crónica. La patología neoplásica supone una tres principales causas de la pérdida del injerte en receptores de trasplante renal, debido a que durante la etapa postrasplante la incidencia de neoplasias es significativamente superior que en la población general. El objetivo de la revisión es investigar cómo afectan las neoplasias a este tipo de pacientes.Métodos: Para realizar la búsqueda se ha formulado una ecuación de búsqueda combinando descriptores del tesauro MESH con operadores booleanos. La búsqueda se ha realizado en PubMed, CINAHL, Biblioteca Cochrane, Web of Science y Scopus. De los 69 artículos cribados, se seleccionaron 23 y además se añadieron otros 6 artículos por otros métodos de selección.Resultados y Discusión: El sarcoma de Kaposi, la enfermedad linfoproliferativa postrasplante y los carcinomas cutáneos no melanoma pueden llegar a desarrollarse hasta 20 veces más frecuentemente que en la población general, así como el cáncer renal hasta 15 veces. Por su parte, los inmunosupresores inhibidores de mTOR han demostrado reducir la incidencia de neoplasias y la prevención a través de intervenciones en educación se ha mostrado efectiva, así como la vacunación, la quimioprevención y las pruebas de detección precoz de cáncer.Conclusiones: El cáncer cutáneo es el cáncer más frecuente en receptores de trasplante renal, la terapia inmunosupresora puede aumentar o disminuir el riesgo de desarrollar una neoplasia por sí sola y las medidas de prevención han demostrado un aumento de la supervivencia.
AB Introduction: Renal transplantation is the treatment that offers the greatest survival and quality of life in chronic kidney disease. Neoplastic pathology is one of the three main causes of graft loss in renal transplant recipients, due to the fact that during the post-transplant stage the incidence of neoplasms is significantly higher than in the general population. The aim of the review is to investigate how neoplasms affect this type of patients.Methods: To carry out the search, a search equation was formulated combining descriptors from the MESH thesaurus with Boolean operators. The search was performed in PubMed, CINAHL, Cochrane Library, Web of Science and Scopus. Of the 69 articles screened, 23 were selected and a further 6 articles were added by other selection methods.Results and Discussion: Kaposi's sarcoma, post-transplant lymphoproliferative disease and nonmelanoma skin carcinomas can develop up to 20 times more frequently than in the general population, as well as renal cancer up to 15 times. For their part, mTOR inhibitor immunosuppressants have been shown to reduce the incidence of neoplasms and prevention through education interventions has been shown to be effective, as well as vaccination, chemoprevention and early cancer screening.Conclusions: Cutaneous cancer is the most common cancer in renal transplant recipients, immunosuppressive therapy alone can increase or decrease the risk of developing a neoplasm, and prevention measures have been shown to increase survival.
YR 2022
FD 2022-05-22
LK https://hdl.handle.net/20.500.14352/3169
UL https://hdl.handle.net/20.500.14352/3169
LA spa
NO 1. Enfermedad Renal Crónica | Nefrología al día [Internet]. [cited 2022 May 17]. Availablefrom: https://nefrologiaaldia.org/es-articulo-enfermedad-renal-cronica-1362. Pautas de derivación a la Unidad de Enfermedad Renal Crónica Avanzada (ERCA) |Nefrología al día [Internet]. [cited 2022 May 17]. Available from:https://www.nefrologiaaldia.org/es-articulo-pautas-derivacion-unidad-enfermedad-renal3743. Resultados globales del trasplante renal | Nefrología al día [Internet]. [cited 2022 May17]. Available from: https://nefrologiaaldia.org/es-articulo-resultados-globales-deltrasplante-renal-584. Neoplasias en el Trasplante Renal | Nefrología al día [Internet]. [cited 2022 May 17].Available from: https://nefrologiaaldia.org/es-articulo-neoplasias-el-trasplante-renal-2115. Rodríguez Campo VA, Paravic Klijn TM. Enfermería basada en la evidencia y gestióndel cuidado. Enfermería Global [Internet]. 2011 Oct [cited 2022 May 17];10(24):0–0.Available from: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1695-61412011000400020&lng=es&nrm=iso&tlng=es6. González P. Enfermería basada en la evidencia. Enferm Endosc Dig. 2019;6(2):31–5.7. El diseño de preguntas clínicas en la práctica basada en la evidencia: modelos deformulación [Internet]. [cited 2022 May 17]. Available from:https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1695-614120160003000168. Actualización en cáncer de piel en receptores de un trasplante de órgano sólido |Nefrología [Internet]. [cited 2022 May 17]. Available from:https://www.revistanefrologia.com/es-actualizacion-cancer-piel-receptores-un-articuloX20137575186222329. Epidemiología del cáncer en el trasplante renal: incidencia, prevalencia y factores deriesgo | Nefrología [Internet]. [cited 2022 May 17]. Available from:https://www.revistanefrologia.com/es-epidemiologia-del-cancer-el-trasplante-articuloX201375751862225910. Webster AC, Rosales BM, Thompson JF. Cancer in Dialysis and Transplant Patients. In:Kidney Transplantation - Principles and Practice. Elsevier; 2019. p. 591–607.11. Trastornos linfoproliferativos postrasplante | Nefrología [Internet]. [cited 2022 May 17].Available from: https://www.revistanefrologia.com/es-trastornos-linfoproliferativospostrasplante-articulo-X201375751862224012. Wójciak M, Gozdowska J, Dęborska-Materkowska D, Perkowska-Ptasińska A,Kosieradzki M, Nazarewski S, et al. Posttransplant Lymphoproliferative Disorder inKidney and Liver Transplant Recipients: A Single-Center Experience. TransplantationProceedings. 2018 Sep 1;50(7):2154–8.13. Machhi R, Mandelbrot DA, Al-Qaoud T, Astor BC, Parajuli S. Characteristics and GraftSurvival of Kidney Transplant Recipients with Renal Cell Carcinoma. American Journalof Nephrology [Internet]. 2020 Oct 1 [cited 2022 May 17];51(10):777–85. Available from:https://www.karger.com/Article/FullText/51061614. Bratt O, Drevin L, Prütz KG, Carlsson S, Wennberg L, Stattin P. Prostate cancer inkidney transplant recipients – a nationwide register study. BJU International [Internet].2020 May 1 [cited 2022 May 17];125(5):679–85. Available from:https://onlinelibrary.wiley.com/doi/full/10.1111/bju.1500215. Wong G, Au E, Badve S v., Lim WH. Breast Cancer and Transplantation. AmericanJournal of Transplantation [Internet]. 2017 Sep 1 [cited 2022 May 17];17(9):2243–53.Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.1436816. Kanaan N, Raggi C, Goffin E, de Meyer M, Mourad M, Jadoul M, et al. Outcome ofhepatitis B and C virus-associated hepatocellular carcinoma occurring after renaltransplantation. Journal of Viral Hepatitis [Internet]. 2017 May 1 [cited 2022 May17];24(5):430–5. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jvh.1265517. Fröhlich FA, Halleck F, Lehner L, Schrezenmeier E v., Naik M, Schmidt D, et al. De-novomalignancies after kidney transplantation: A long-term observational study. PLOS ONE[Internet]. 2020 Nov 1 [cited 2022 May 17];15(11):e0242805. Available from:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.024280518. Prevención del cáncer postrasplante renal: de los factores clásicos a lainmunosupresión | Nefrología [Internet]. [cited 2022 May 18]. Available from:https://www.revistanefrologia.com/es-prevencion-del-cancer-postrasplante-renal-articuloX201375751862227519. Murray SL, Daly FE, O’Kelly P, O’Leary E, Deady S, O’Neill JP, et al. The impact ofswitching to mTOR inhibitor-based immunosuppression on long-term non-melanomaskin cancer incidence and renal function in kidney and liver transplant recipients.https://doi.org/101080/0886022X20201785499 [Internet]. 2020 Jan 1 [cited 2022 May18];42(1):607–12. Available from:https://www.tandfonline.com/doi/abs/10.1080/0886022X.2020.178549920. Lim LM, Kung LF, Kuo MC, Huang AM, Kuo HT. Timing of mtori usage and outcomes inkidney transplant recipients. International Journal of Medical Sciences.2021;18(5):1179–84.21. Ying T, Wong G, Lim W, Kanellis J, Pilmore H, Campbell S, et al. De novo or earlyconversion to everolimus and long-term cancer outcomes in kidney transplant recipients:A trial-based linkage study. American Journal of Transplantation [Internet]. 2018 Dec 1[cited 2022 May 18];18(12):2977–86. Available from:https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.1494822. Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ. The risk of cancer inkidney transplant recipients may be reduced in those maintained on everolimus andreduced cyclosporine. Kidney International [Internet]. 2017 Apr 1 [cited 2022 May18];91(4):954–63. Available from: http://www.kidneyinternational.org/article/S0085253816306615/fulltext23. Hirunsatitpron P, Hanprasertpong N, Noppakun K, Pruksakorn D, Teekachunhatean S,Koonrungsesomboon N. Mycophenolic acid and cancer risk in solid organ transplantrecipients: Systematic review and meta-analysis. British Journal of ClinicalPharmacology [Internet]. 2022 Feb 1 [cited 2022 May 18];88(2):476–89. Available from:https://onlinelibrary.wiley.com/doi/full/10.1111/bcp.1497924. Wang M, Mittal A, Colegio OR. Belatacept reduces skin cancer risk in kidney transplantrecipients. J Am Acad Dermatol. 2020 Apr;82(4):996–8.25. Turshudzhyan A. Post-renal transplant malignancies: Opportunities for prevention andearly screening. Cancer Treatment and Research Communications. 2021 Jan1;26:100283.26. Evaluación y detección precoz del cáncer antes y después del trasplante renal |Nefrología [Internet]. [cited 2022 May 18]. Available from:https://www.revistanefrologia.com/es-evaluacion-deteccion-precoz-del-cancer-articuloX201375751862226727. Rashti SL. Themes in Literature Related to Incidence, Risk, and Prevention of Cancer inSolid-Organ Transplantation Recipients on Immunosuppressive Therapy. CancerNursing [Internet]. 2019 Jan 1 [cited 2022 May 18];42(1):E28–35. Available from:https://journals.lww.com/cancernursingonline/Fulltext/2019/01000/Themes_in_Literature_Related_to_Incidence,_Risk,.15.aspx28. Patel PH, Bibee K, Lim G, Malik SM, Wu C, Pugliano-Mauro M. Evaluating Retention ofSkin Cancer Education in Kidney Transplant Recipients Reveals a Window ofOpportunity for Re-education. Transplantation Proceedings. 2017 Jul 1;49(6):1318–24.29. Gellén E, Papp BG, Janka EA, Gáll T, Paragh G, Emri G, et al. Comparison of pre- andpost-transplant sun-safe behavior of kidney transplant recipients: What is needed toimprove? Photodermatology, Photoimmunology & Photomedicine [Internet]. 2018 Sep 1[cited 2022 May 18];34(5):322–9. Available from:https://onlinelibrary.wiley.com/doi/full/10.1111/phpp.1238730. Leung VKY, Dobbinson SJ, Goodman DJ, Kanellis J, Chong AH. Skin cancer history,sun-related attitudes, behaviour and sunburn among renal transplant recipients versusgeneral population. Australasian Journal of Dermatology [Internet]. 2018 May 1 [cited2022 May 18];59(2):e106–13. Available from:https://onlinelibrary.wiley.com/doi/full/10.1111/ajd.1259131. Miura K, Way M, Jiyad Z, Marquart L, Plasmeijer EI, Campbell S, et al. Omega-3 fattyacid intake and decreased risk of skin cancer in organ transplant recipients. EuropeanJournal of Nutrition 2020 60:4 [Internet]. 2020 Sep 9 [cited 2022 May 18];60(4):1897–905. Available from: https://link.springer.com/article/10.1007/s00394-020-02378-y32. Yélamos O, Halpern AC, Weinstock MA. Reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.’ British Journal of Dermatology [Internet]. 2017 Feb 1 [cited 2022 May 18];176(2):551–2.Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.1520333. Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Prevention of nonmelanoma skin cancers with nicotinamide in transplant recipients: a case-control study.European Journal of Dermatology [Internet]. 2017 Jul 1 [cited 2022 May 18];27(4):382–5.Available from: http://www.jle.com/fr/revues/ejd/edocs/prevention_of_non_melanoma_skin_cancers_with_nicotinamide_in_transplant_recipients_a_case_control_study_309635/article.phtml?tab=texte34. Thet Z, Lam AK, Ranganathan D, Aung SY, Han T, Khoo TK. Reducing non-melanomaskin cancer risk in renal transplant recipients. Nephrology [Internet]. 2021 Nov 1 [cited2022 May 18];26(11):907–19. Available from:https://onlinelibrary.wiley.com/doi/full/10.1111/nep.1393935. Reinholdt K, Thomsen LT, Dehlendorff C, Larsen HK, Sørensen SS, Hædersdal M, et al.Human papillomavirus-related anogenital premalignancies and cancer in renal transplantrecipients: A Danish nationwide, registry-based cohort study. International Journal ofCancer [Internet]. 2020 May 1 [cited 2022 May 19];146(9):2413–22. Available from:https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.3256536. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. ThePRISMA 2020 statement: An updated guideline for reporting systematic reviews. Journalof Clinical Epidemiology. 2021 Jun 1;134:178–89.
NO Mi Trabajo de Fin de Grado es una revisión bibliográfica que tiene el objetivo de investigar, averiguar, conocer y analizar cómo afecta la patología neoplásica en la supervivencia de un paciente que ha sido receptor de un trasplante renal. Este Trabajo de Fin de Grado ha sido tutorizado por la profesora del Hospital Universitario 12 de Octubre, María José Durá, que es profesora asociada de la Universidad Complutense de Madrid (UCM) en este hospital. El mismo donde realicé mi defensa de este trabajo ante un tribunal compuesto por profesoras asociadas a la UCM de este hospital. Este Trabajo de Fin de Grado ha obtenido una calificación de Matrícula de Honor.
DS Docta Complutense
RD 6 may 2024